<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1087">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146999</url>
  </required_header>
  <id_info>
    <org_study_id>43QM2106</org_study_id>
    <nct_id>NCT05146999</nct_id>
  </id_info>
  <brief_title>Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines</brief_title>
  <official_title>A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Assess Aesthetic Improvement and Onset of QM1114-DP Treatment Effect in Subjects With Moderate to Severe Glabellar Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the aesthetic improvement and onset of QM1114-DP&#xD;
      treatment for subjects with moderate to severe glabellar lines&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Assess Aesthetic&#xD;
      Improvement and Onset of QM1114-DP Treatment Effect in Subjects with Moderate to Severe&#xD;
      Glabellar Lines&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2022</start_date>
  <completion_date type="Anticipated">March 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responders in QM1114-DP versus Placebo using the Global Aesthetic Improvement Scale (GAIS) at maximum frown at Month 1</measure>
    <time_frame>1 month</time_frame>
    <description>Responder Rate is based on the 7-point GAIS and is defined as a subject who responds at least Improved on the GAIS at maximum frown</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Glabellar Frown Lines</condition>
  <arm_group>
    <arm_group_label>Active arm - QM1114-DP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a Botulinum Toxin Type A (BoNT-A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactive arm - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A buffered solution,</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>QM1114-DP</intervention_name>
    <description>QM1114-DP, a Botulinum Toxin Type A (BoNT-A); Intramuscular injection</description>
    <arm_group_label>Active arm - QM1114-DP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, A buffered solution, Intramuscular injection</description>
    <arm_group_label>Inactive arm - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female 18 years or older&#xD;
&#xD;
          -  Moderate to severe GL at maximum frown as assessed by the Investigator&#xD;
&#xD;
          -  Moderate to severe GL at maximum frown as assessed by the subject&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous use of any botulinum toxin in facial areas within 9 months prior to study&#xD;
             treatment&#xD;
&#xD;
          -  Female who is pregnant, breast feeding or intends to conceive a child during the&#xD;
             study.&#xD;
&#xD;
          -  Known allergy to hypersensitivity or any component of the Investigational product&#xD;
&#xD;
          -  (QM1114-DP) or any botulinum toxin serotype&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Galderma Aesthetics</last_name>
    <phone>817-961-5655</phone>
    <email>aetheticclinicaltrials@galderma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Skin Wellness Dermatology</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Cooridnator</last_name>
      <phone>205-871-7332</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moradi MD</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Research Institute, LLC</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aesthetic Solutions, PA</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Aesthetics</name>
      <address>
        <city>Spring</city>
        <state>Texas</state>
        <zip>77388</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 31, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

